TG Therapeutics stock surged after H.C. Wainwright raised its price target to $70, indicating a potential upside of 76.1%. On the same day, the company reported Q1 2026 revenues of approximately $205 million, driven by BRIUMVI sales. TG Therapeutics also raised its full-year global revenue target to approximately $925 million.
